The S&P 500® Index is an unmanaged index of common stock performance. You cannot invest directly in an index.
Consider these risks before investing: Biology revolution companies face intense competition and potentially rapid product obsolescence. Biology revolution companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations. The potential for an increased amount of required disclosure or lack of access to proprietary scientific information could negatively impact the performance of these companies. Investments in small and/or midsize companies increase the risk of greater price fluctuations. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. The value of investments in the fund's portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general economic, political, or financial market conditions; investor sentiment and market perceptions; government actions; geopolitical events or changes; and factors related to a specific issuer, geography, industry, or sector. These and other factors may lead to increased volatility and reduced liquidity in the fund's portfolio holdings. As a non-diversified fund, the fund invests in fewer issuers and is more vulnerable than a more broadly diversified fund to fluctuations in the values of the securities it holds. Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund's other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund.Active ETF
Putnam BioRevolution ETF (Class A) (SYNB)
Investing in companies that are leveraging innovation within biology
Harnessing the biorevolution for investors
The revolution in biology and life sciences is unleashing new potential for innovation across many sectors, creating opportunities for investors.
Read more
NAV as of 05/31/23
$26.64
Market data all data below as of 05/31/23
Closing market price | $26.67 |
30-day median bid-ask spread | 0.11% |
Day high | $26.67 |
Day low | $26.67 |
Premium/Discount | 0.11% |
30-day average trading volume | 172 |
Net assets and outstanding shares | Download CSV |
How to buy Putnam ETFs
Putnam ETFs can be purchased and sold the same way you would buy or sell a stock — through most self-directed brokers or with the guidance of your advisor. Opening an online, self-directed brokerage account provides investors with:
- Accessibility to a variety of investment products
- Tools to help you build and optimize your portfolio
- Flexibility and freedom of managing your investment portfolio
ETF facts as of 04/30/23
SYNB
746729805
09/29/22
$4.80M
0.70%
Blend
--
Annually
45
April
Objective
Putnam BioRevolution ETF seeks long term capital appreciation.
Strategy and process
- Pursues transformative growth across sectorsThe economic impact of the biology revolution is spreading beyond health care, with potential to transform multiple sectors and drive investment opportunities.
- Collaborative research processA benchmark-agnostic approach leverages unique, integrated insights of Putnam sector analysts and the Sustainable Equity team.
- Concentrated portfolioThe manager seeks outperformance by investing in 30-50 high-conviction stocks selected through disciplined portfolio construction and risk management.
Management team
William C. Rives, CFA
Portfolio Manager, Analyst
10 years in industry
10 years at Putnam Investments

Literature
Fund information |
|
Fact Sheet (PDF) |
|
Legal documents |
|
Summary Prospectus (PDF) |
|
Statutory Prospectus (PDF) |
|
Statement of Additional Information (SAI) (PDF) |
|
Semiannual Report (PDF) |
|
Related/Investment insights
What is the biorevolution?
The revolution in biology and life sciences is unleashing new potential for innovation across many sectors, creating opportunities for investors.Economic moats | Active investors seek wider moats
Economic moats, also called business moats, are competitive advantages that help a company maintain long-term profits and market share over competitors.How an active core strategy can benefit equity investors
An active core strategy backed by fundamental, sector-based research has demonstrated impressive long-term performance versus passive strategies.Performance
Total return (%) as of 03/31/23
Cumulative Total return (%) as of 03/31/23
Cumulative performance | 1 yr. | 3 yrs. | 5 yrs. | Life |
---|---|---|---|---|
Net asset value | -- | -- | -- | 9.18% |
Market price | -- | -- | -- | 9.10% |
Current performance may be lower or higher than the quoted past performance, which cannot guarantee future results. Share price, principal value, and return will vary, and you may have a gain or loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. Returns for periods of less than one year are not annualized. Market performance is determined using the bid/ask midpoint at 4:00 p.m. Eastern time. Market performance does not represent the returns you would receive if you traded shares at other times throughout the day.
Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV, and are not individually redeemed from the fund. Brokerage commissions will reduce returns.
The fund has limited public trading history.
Performance snapshot
Net asset value | Market price | ||
---|---|---|---|
1 mt. as of 05/31/23 | -2.94% | -2.73% | |
YTD as of 05/31/23 | 2.65% | 2.68% | |
Historical premium/discount
Number of days at premium | -- |
Number of days at NAV | -- |
Number of days at discount | -- |
Compare
See how this fund stacks up against its peers with FundVisualizer®
New to FundVisualizer? Watch tutorials on how to get started.
For more tutorials, please visit fundvisualizer.com
** FundVisualizer comparison based on Putnam fund versus the largest fund in its Morningstar category.
Holdings
Portfolio holdings
Full portfolio holdings | Download XLSX |
---|
Bio-Rad Laboratories | 6.88% |
---|---|
Thermo Fisher Scientific | 6.50% |
Alphabet | 5.19% |
Eli Lilly | 4.12% |
Nvidia Corp | 3.92% |
Novozymes A/S - B Shares | 3.88% |
Ingevity Corp | 3.70% |
Lululemon Athletica | 3.65% |
Corteva | 3.64% |
Dupont De Nemours | 3.33% |
Top 10 holdings, percent of portfolio | 44.82% |
Top 10 holdings as of 04/30/23 | |
---|---|
Bio-Rad Laboratories | |
Thermo Fisher Scientific | |
Alphabet | |
Eli Lilly | |
Nvidia Corp | |
Novozymes A/S - B Shares | |
Ingevity Corp | |
Lululemon Athletica | |
Corteva | |
Dupont De Nemours | |
Holdings represent 44.82% of portfolio |
Top 10 holdings as of 03/31/23 | |
---|---|
Bio-Rad Laboratories | |
Thermo Fisher Scientific | |
Danaher Corp | |
Alphabet | |
Nvidia Corp | |
Lululemon Athletica | |
Novozymes A/S - B Shares | |
Corteva | |
Eli Lilly | |
Ingevity Corp | |
Holdings represent 46.76% of portfolio |
Top 10 holdings as of 02/28/23 | |
---|---|
Bio-Rad Laboratories | |
Thermo Fisher Scientific | |
Danaher Corp | |
Alphabet | |
Corteva | |
Nvidia Corp | |
Novozymes A/S - B Shares | |
Lululemon Athletica | |
Astrazeneca | |
Avantor | |
Holdings represent 43.39% of portfolio |
Top 10 holdings as of 01/31/23 | |
---|---|
Thermo Fisher Scientific | |
Bio-Rad Laboratories | |
Danaher Corp | |
Alphabet | |
Avantor | |
Corteva | |
Merck | |
Eli Lilly | |
Astrazeneca | |
Dupont De Nemours | |
Holdings represent 43.63% of portfolio |
Sector weightings as of 04/30/23
Health care | 53.14% |
---|---|
Materials | 21.66% |
Consumer discretionary | 6.84% |
Consumer staples | 5.47% |
Communication services | 5.19% |
Information technology | 3.92% |
Cash and net other assets | 3.79% |
0
Sectors will vary over time.
Equity statistics as of 04/30/23
Median market cap | $24.73B |
---|---|
Weighted average market cap | $177.99B |
Price to book | 3.46 |
Price to earnings | 32.79 |